Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of non-driver gene mutations on thrombo-haemorrhagic events in ET patients.

British journal of haematology - 1 Jan 2024

Furuya Chiho, Morishita Soji, Hashimoto Yoshinori, Inano Tadaaki, Ochiai Tomonori, Shirane Shuichi, Edahiro Yoko, Araki Marito, Ando Miki, Komatsu Norio

Abstract excerpt

Risk-adapted therapy is recommended to prevent major clinical complications, such as thrombo-haemorrhagic events, in patients with essential thrombocythaemia (ET). In this study, we analysed the association between non-driver gene mutations and thrombo-haemorrhagic events in 579 patients with ET. ASXL1 and TP53 mutations were frequently identified in patients with ET complicated by thrombosis (22.7% and 23.1%,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Eosinophilic Disorders and Syndromes
Share to Hemorrhage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kruppel-like factors research

Share to Mutation

Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Share to Prognosis

Share to Thrombocythemia, Essential

Share to Thrombosis

Source

Identifiers

PMID: 37920129
DOI: 10.1111/bjh.19177

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of non-driver gene mutations on thrombo-haemorrhagic events in ET patients.PMID 37920129Read ↗

Thrombotic Prediction Model Based on Epigenetic Regulator Mutations in Essential Thrombocythemia Patients Using Survival Analysis in Recurrent Events.Semantic proximity Read ↗

The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.Semantic proximity Read ↗

Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience.Semantic proximity Read ↗

Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China.Semantic proximity Read ↗

MPL gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan.Semantic proximity Read ↗

Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia.Semantic proximity Read ↗

JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.Semantic proximity Read ↗

Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia.Semantic proximity Read ↗

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.Semantic proximity Read ↗

Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.Semantic proximity Read ↗

Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.Semantic proximity Read ↗

[Gene mutation spectrum and clinical characteristics analysis of 178 patients with essential thrombocytosis].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.